Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...

T-Mobile, Toyota Motor, Vertex Pharmaceuticals, BK Technologies and Servotronics are part of the Zacks top Analyst Blog.

Shares of Vertex Pharmaceuticals Inc. VRTX slid 0.46% to $408.76 Friday, on what proved to be an all-around rough trading ...

This was the stock's fourth consecutive day of gains.

Different genetic mutations cause different problems with this particular protein -- so CFTR modulators generally don't work ...

We recently compiled a list of the Jim Cramer Discusses 17 Stocks And Blasts Zero Day Options. In this article, we are going ...

Vertex Pharmaceuticals announced FDA approval for Alyftrek, which expands the company's CF franchise to address around 6,000 ...

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today. The company’s ...

Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat ...

We recently compiled a list of the Jim Cramer Talked About These 17 Stocks After The Fed’s Rate Cut. In this article, we are ...

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $408.18, denoting a +0.72% change from the preceding trading day.